{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:06:22Z","timestamp":1740107182805,"version":"3.37.3"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071485"],"award-info":[{"award-number":["82071485"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-03626-5","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T11:32:33Z","timestamp":1735558353000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world individual and comparative analysis of adverse event reporting for adalimumab and etanercept using public FDA adverse event reporting system data"],"prefix":"10.1007","volume":"317","author":[{"given":"Xiaoke","family":"Dou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"issue":"9583","key":"3626_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","volume":"370","author":"CE Griffiths","year":"2007","unstructured":"Griffiths CE, Barker JN (2007) Pathogenesis and clinical features of psoriasis. Lancet 370(9583):263\u2013271","journal-title":"Lancet"},{"issue":"10281","key":"3626_CR2","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM et al (2021) Psoriasis Lancet 397(10281):1301\u20131315","journal-title":"Psoriasis Lancet"},{"issue":"11","key":"3626_CR3","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1111\/jdv.18437","volume":"36","author":"Q Luo","year":"2022","unstructured":"Luo Q et al (2022) Psoriasis may increase the risk of lung cancer: a two-sample mendelian randomization study. J Eur Acad Dermatol Venereol 36(11):2113\u20132119","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3626_CR4","doi-asserted-by":"publisher","first-page":"115078","DOI":"10.1016\/j.psychres.2023.115078","volume":"321","author":"L Liu","year":"2023","unstructured":"Liu L et al (2023) Epidemiology of mental health comorbidity in patients with psoriasis: an analysis of trends from 1986 to 2019. Psychiatry Res 321:115078","journal-title":"Psychiatry Res"},{"issue":"6","key":"3626_CR5","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/j.jaad.2022.07.060","volume":"87","author":"A Ogdie","year":"2022","unstructured":"Ogdie A et al (2022) Prospective cohort study of psoriatic arthritis risk in patients with psoriasis in a real-world psoriasis registry. J Am Acad Dermatol 87(6):1303\u20131311","journal-title":"J Am Acad Dermatol"},{"issue":"5s","key":"3626_CR6","first-page":"6","volume":"102","author":"JM Hugh","year":"2018","unstructured":"Hugh JM, Weinberg JM (2018) Update on the pathophysiology of psoriasis. Cutis 102(5s):6\u201312","journal-title":"Cutis"},{"issue":"19","key":"3626_CR7","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C (2020) Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA 323(19):1945\u20131960","journal-title":"JAMA"},{"key":"3626_CR8","doi-asserted-by":"crossref","unstructured":"Zhou C et al (2023) Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting System (FAERS) database. EClinicalMedicine. 59:101967","DOI":"10.1016\/j.eclinm.2023.101967"},{"key":"3626_CR9","doi-asserted-by":"publisher","first-page":"921084","DOI":"10.3389\/fphar.2022.921084","volume":"13","author":"J Wang","year":"2022","unstructured":"Wang J et al (2022) Hepatitis B Virus Reactivation and Mycobacterial infections Associated with Ustekinumab: a retrospective study of an International Pharmacovigilance Database. Front Pharmacol 13:921084","journal-title":"Front Pharmacol"},{"key":"3626_CR10","doi-asserted-by":"publisher","first-page":"1169735","DOI":"10.3389\/fimmu.2023.1169735","volume":"14","author":"Y Shu","year":"2023","unstructured":"Shu Y et al (2023) Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system. Front Immunol 14:1169735","journal-title":"Front Immunol"},{"key":"3626_CR11","doi-asserted-by":"publisher","first-page":"862508","DOI":"10.3389\/fphar.2022.862508","volume":"13","author":"Y Shu","year":"2022","unstructured":"Shu Y et al (2022) Post-marketing safety concerns with Secukinumab: a disproportionality analysis of the FDA adverse event reporting system. Front Pharmacol 13:862508","journal-title":"Front Pharmacol"},{"issue":"4","key":"3626_CR12","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/apt.12385","volume":"38","author":"P Deepak","year":"2013","unstructured":"Deepak P et al (2013) Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration adverse event reporting system. Aliment Pharmacol Ther 38(4):388\u2013396","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"3626_CR13","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1080\/14712598.2021.1948529","volume":"21","author":"F Mazhar","year":"2021","unstructured":"Mazhar F et al (2021) The impact of anti-TNF\u03b1 agents on weight-related changes: new insights from a real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS) database. Expert Opin Biol Ther 21(9):1281\u20131290","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"3626_CR14","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/phar.1731","volume":"36","author":"M Guo","year":"2016","unstructured":"Guo M et al (2016) The risk of Glioblastoma with TNF inhibitors. Pharmacotherapy 36(4):449\u2013454","journal-title":"Pharmacotherapy"},{"issue":"4","key":"3626_CR15","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00296-014-3133-9","volume":"35","author":"A Krishnan","year":"2015","unstructured":"Krishnan A, Stobaugh DJ, Deepak P (2015) Assessing the likelihood of new-onset inflammatory bowel disease following tumor necrosis factor-alpha inhibitor therapy for rheumatoid arthritis and juvenile rheumatoid arthritis. Rheumatol Int 35(4):661\u2013668","journal-title":"Rheumatol Int"},{"issue":"2","key":"3626_CR16","doi-asserted-by":"publisher","first-page":"102","DOI":"10.7150\/ijms.17025","volume":"14","author":"T Matsui","year":"2017","unstructured":"Matsui T et al (2017) Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-\u03b1 (TNF-\u03b1) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004\u20132015. Int J Med Sci 14(2):102\u2013109","journal-title":"Int J Med Sci"},{"issue":"3","key":"3626_CR17","doi-asserted-by":"publisher","first-page":"267","DOI":"10.15403\/jgld.2014.1121.233.mrmk","volume":"23","author":"MR McKenna","year":"2014","unstructured":"McKenna MR, Stobaugh DJ, Deepak P (2014) Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-\u03b1 inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration adverse event reporting system. J Gastrointestin Liver Dis 23(3):267\u2013271","journal-title":"J Gastrointestin Liver Dis"},{"key":"3626_CR18","doi-asserted-by":"crossref","unstructured":"Jedlowski PM (2023) Association of non-melanoma skin cancers, melanoma and merkel cell carcinoma with dermatologic medications, a case control pharmacovigilance study of the FDA Adverse Events Reporting System. Dermatology","DOI":"10.1159\/000530107"},{"issue":"8","key":"3626_CR19","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/14740338.2019.1630063","volume":"18","author":"C Chen","year":"2019","unstructured":"Chen C et al (2019) Comparison of post-marketing surveillance approaches regarding infections related to tumor necrosis factor inhibitors (TNFi\u2019s) used in treatment of autoimmune diseases. Expert Opin Drug Saf 18(8):733\u2013744","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"3626_CR20","first-page":"351","volume":"3","author":"KP Machold","year":"2003","unstructured":"Machold KP, Smolen JS (2003) Adalimumab - a new TNF-alpha antibody for treatment of inflammatory joint disease. Expert Opin Biol Ther 3(2):351\u2013360","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"3626_CR21","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1111\/bjd.21797","volume":"187","author":"LS van der Schoot","year":"2022","unstructured":"van der Schoot LS et al (2022) Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab. Br J Dermatol 187(6):1028\u20131030","journal-title":"Br J Dermatol"},{"issue":"4","key":"3626_CR22","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","volume":"72","author":"GR Burmester","year":"2013","unstructured":"Burmester GR et al (2013) Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn\u2019s disease. Ann Rheum Dis 72(4):517\u2013524","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3626_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/nrgastro.2016.155","volume":"14","author":"S Danese","year":"2017","unstructured":"Danese S, Bonovas S, Peyrin-Biroulet L (2017) Biosimilars in IBD: from theory to practice. Nat Rev Gastroenterol Hepatol 14(1):22\u201331","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"3626_CR24","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s40272-022-00501-6","volume":"24","author":"J Zitouni","year":"2022","unstructured":"Zitouni J et al (2022) Effectiveness and safety of Adalimumab, Etanercept and Ustekinumab for severe psoriasis in children under 12 years of age: a french-italian Daily Practice Cohort (BiPe Jr). Paediatr Drugs 24(3):281\u2013292","journal-title":"Paediatr Drugs"},{"issue":"Suppl 1","key":"3626_CR25","doi-asserted-by":"publisher","first-page":"i46","DOI":"10.1136\/ard.59.suppl_1.i46","volume":"59","author":"G Spencer-Green","year":"2000","unstructured":"Spencer-Green G (2000) Etanercept (Enbrel): update on therapeutic use. Ann Rheum Dis 59(Suppl 1):i46\u2013i49","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3626_CR26","doi-asserted-by":"publisher","first-page":"e0157753","DOI":"10.1371\/journal.pone.0157753","volume":"11","author":"R B\u00f6hm","year":"2016","unstructured":"B\u00f6hm R et al (2016) OpenVigil FDA - Inspection of U.S. American adverse drug events Pharmacovigilance Data and Novel Clinical Applications. PLoS ONE 11(6):e0157753","journal-title":"PLoS ONE"},{"issue":"11","key":"3626_CR27","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1111\/bcp.14868","volume":"87","author":"R B\u00f6hm","year":"2021","unstructured":"B\u00f6hm R et al (2021) Pharmacovigilance-based drug repurposing: the search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections. Br J Clin Pharmacol 87(11):4421\u20134431","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"3626_CR28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/jamadermatol.2020.3385","volume":"157","author":"DD Nguyen","year":"2021","unstructured":"Nguyen DD et al (2021) Investigation of suicidality and psychological adverse events in patients treated with Finasteride. JAMA Dermatol 157(1):35\u201342","journal-title":"JAMA Dermatol"},{"key":"3626_CR29","doi-asserted-by":"publisher","first-page":"m1590","DOI":"10.1136\/bmj.m1590","volume":"369","author":"R Parisi","year":"2020","unstructured":"Parisi R et al (2020) National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ 369:m1590","journal-title":"BMJ"},{"issue":"5","key":"3626_CR30","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/bjd.21768","volume":"187","author":"SE Choon","year":"2022","unstructured":"Choon SE et al (2022) Incidence and prevalence of psoriasis in multiethnic Johor Bahru, Malaysia: a population-based cohort study using electronic health data routinely captured in the Teleprimary Care (TPC\u00ae) clinical information system from 2010 to 2020: classification: Epidemiology. Br J Dermatol 187(5):713\u2013721","journal-title":"Br J Dermatol"},{"issue":"5","key":"3626_CR31","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/pde.12568","volume":"32","author":"A Cantarutti","year":"2015","unstructured":"Cantarutti A et al (2015) Epidemiology of frequently occurring skin diseases in Italian Children from 2006 to 2012: a Retrospective, Population-based study. Pediatr Dermatol 32(5):668\u2013678","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"3626_CR32","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/bjd.15021","volume":"176","author":"DA Springate","year":"2017","unstructured":"Springate DA et al (2017) Incidence, prevalence and mortality of patients with psoriasis: a U.K. population-based cohort study. Br J Dermatol 176(3):650\u2013658","journal-title":"Br J Dermatol"},{"issue":"7","key":"3626_CR33","doi-asserted-by":"publisher","first-page":"808","DOI":"10.2340\/00015555-2672","volume":"97","author":"A Egeberg","year":"2017","unstructured":"Egeberg A et al (2017) Incidence and prevalence of Psoriasis in Denmark. Acta Derm Venereol 97(7):808\u2013812","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"3626_CR34","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jaad.2008.10.062","volume":"60","author":"M Icen","year":"2009","unstructured":"Icen M et al (2009) Trends in incidence of adult-onset psoriasis over three decades: a population-based study. J Am Acad Dermatol 60(3):394\u2013401","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"3626_CR35","doi-asserted-by":"publisher","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","volume":"28","author":"JE Signorovitch","year":"2010","unstructured":"Signorovitch JE et al (2010) Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. PharmacoEconomics 28(10):935\u2013945","journal-title":"PharmacoEconomics"},{"key":"3626_CR36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-5945-13-9","volume":"13","author":"JM Khalid","year":"2013","unstructured":"Khalid JM et al (2013) Treatment and referral patterns for psoriasis in United Kingdom primary care: a retrospective cohort study. BMC Dermatol 13:9","journal-title":"BMC Dermatol"},{"issue":"2","key":"3626_CR37","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/d41573-022-00215-x","volume":"22","author":"A Eccleston","year":"2023","unstructured":"Eccleston A (2023) Cartilage regeneration for osteoarthritis. Nat Rev Drug Discov 22(2):96","journal-title":"Nat Rev Drug Discov"},{"issue":"28","key":"3626_CR38","doi-asserted-by":"publisher","first-page":"e21131","DOI":"10.1097\/MD.0000000000021131","volume":"99","author":"A Vasudeva","year":"2020","unstructured":"Vasudeva A et al (2020) Assessment of pain and structure after an intra-articular injection of adalimumab in osteoarthritis of the knee: a case report. Med (Baltim) 99(28):e21131","journal-title":"Med (Baltim)"},{"issue":"1","key":"3626_CR39","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1177\/0300060517723182","volume":"46","author":"J Wang","year":"2018","unstructured":"Wang J (2018) Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: an open-label randomized controlled trial. J Int Med Res 46(1):326\u2013334","journal-title":"J Int Med Res"},{"issue":"7","key":"3626_CR40","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.joca.2018.02.899","volume":"26","author":"D Aitken","year":"2018","unstructured":"Aitken D et al (2018) A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand OsteoaRthritis - the HUMOR trial. Osteoarthritis Cartilage 26(7):880\u2013887","journal-title":"Osteoarthritis Cartilage"},{"issue":"2","key":"3626_CR41","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jbspin.2016.03.014","volume":"84","author":"A Hoxha","year":"2017","unstructured":"Hoxha A et al (2017) Pregnancy and foetal outcomes following anti-tumor necrosis factor alpha therapy: a prospective multicentre study. Joint Bone Spine 84(2):169\u2013173","journal-title":"Joint Bone Spine"},{"issue":"2","key":"3626_CR42","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1001\/jamadermatol.2013.8347","volume":"150","author":"SP Menting","year":"2014","unstructured":"Menting SP et al (2014) Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up. JAMA Dermatol 150(2):130\u2013136","journal-title":"JAMA Dermatol"},{"issue":"3","key":"3626_CR43","first-page":"603","volume":"59","author":"P Drechsel","year":"2020","unstructured":"Drechsel P et al (2020) Pregnancy outcomes in DMARD-exposed patients with juvenile idiopathic arthritis-results from a JIA biologic registry. Rheumatology (Oxford) 59(3):603\u2013612","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"3626_CR44","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S2468-1253(21)00393-9","volume":"7","author":"JD Schulberg","year":"2022","unstructured":"Schulberg JD et al (2022) Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn\u2019s disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial. Lancet Gastroenterol Hepatol 7(4):318\u2013331","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"3626_CR45","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1136\/gut.2008.159251","volume":"58","author":"JF Colombel","year":"2009","unstructured":"Colombel JF et al (2009) Adalimumab for the treatment of fistulas in patients with Crohn\u2019s disease. Gut 58(7):940\u2013948","journal-title":"Gut"},{"issue":"3","key":"3626_CR46","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.dld.2018.12.010","volume":"51","author":"M Chambaz","year":"2019","unstructured":"Chambaz M et al (2019) Deep remission on magnetic resonance imaging impacts outcomes of perianal fistulizing Crohn\u2019s disease. Dig Liver Dis 51(3):358\u2013363","journal-title":"Dig Liver Dis"},{"issue":"2","key":"3626_CR47","doi-asserted-by":"publisher","first-page":"e2036315","DOI":"10.1001\/jamanetworkopen.2020.36315","volume":"4","author":"FI Scott","year":"2021","unstructured":"Scott FI et al (2021) Association between Statin Use at the time of intra-abdominal surgery and postoperative adhesion-related complications and small-bowel obstruction. JAMA Netw Open 4(2):e2036315","journal-title":"JAMA Netw Open"},{"issue":"2","key":"3626_CR48","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1007\/s10620-016-4400-2","volume":"62","author":"PG Kotze","year":"2017","unstructured":"Kotze PG et al (2017) Tumor necrosis factor alpha inhibitors did not influence postoperative morbidity after Elective Surgical resections in Crohn\u2019s Disease. Dig Dis Sci 62(2):456\u2013464","journal-title":"Dig Dis Sci"},{"issue":"5","key":"3626_CR49","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10067-009-1346-1","volume":"29","author":"Y Hirano","year":"2010","unstructured":"Hirano Y et al (2010) Influences of anti-tumour necrosis factor agents on postoperative recovery in patients with rheumatoid arthritis. Clin Rheumatol 29(5):495\u2013500","journal-title":"Clin Rheumatol"},{"issue":"8","key":"3626_CR50","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1002\/jbmr.3449","volume":"33","author":"T Yoshimoto","year":"2018","unstructured":"Yoshimoto T et al (2018) Second-generation SYK inhibitor Entospletinib ameliorates fully established inflammation and Bone Destruction in the Cherubism Mouse Model. J Bone Min Res 33(8):1513\u20131519","journal-title":"J Bone Min Res"},{"issue":"1","key":"3626_CR51","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13075-021-02448-4","volume":"23","author":"S Toyama","year":"2021","unstructured":"Toyama S et al (2021) Comprehensive assessment of alterations in hand deformities over 11 years in patients with rheumatoid arthritis using cluster analysis and analysis of covariance. Arthritis Res Ther 23(1):66","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"3626_CR52","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s00296-020-04588-3","volume":"40","author":"R Li","year":"2020","unstructured":"Li R et al (2020) Tocilizumab treatment in Felty\u2019s syndrome. Rheumatol Int 40(7):1143\u20131149","journal-title":"Rheumatol Int"},{"issue":"4","key":"3626_CR53","doi-asserted-by":"publisher","first-page":"105183","DOI":"10.1016\/j.jbspin.2021.105183","volume":"88","author":"C Ngoufack","year":"2021","unstructured":"Ngoufack C et al (2021) Mitral valve granulomatosis: a paradoxical reaction complicating etanercept treatment in rheumatoid arthritis. A case report. Joint Bone Spine 88(4):105183","journal-title":"Joint Bone Spine"},{"issue":"8","key":"3626_CR54","first-page":"e5419","volume":"11","author":"A Ammar","year":"2019","unstructured":"Ammar A et al (2019) Etanercept-associated Nephropathy. Cureus 11(8):e5419","journal-title":"Cureus"},{"issue":"5","key":"3626_CR55","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s10067-020-05459-9","volume":"40","author":"DPA de Cerqueira","year":"2021","unstructured":"de Cerqueira DPA et al (2021) Biological therapy in rheumatoid vasculitis: a systematic review. Clin Rheumatol 40(5):1717\u20131724","journal-title":"Clin Rheumatol"},{"issue":"5","key":"3626_CR56","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SA (2006) Under-reporting of adverse drug reactions: a systematic review. Drug Saf 29(5):385\u2013396","journal-title":"Drug Saf"},{"key":"3626_CR57","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","volume":"346","author":"Y Jiang","year":"2024","unstructured":"Jiang Y et al (2024) Safety assessment of Brexpiprazole: real-world adverse event analysis from the FAERS database. J Affect Disord 346:223\u2013229","journal-title":"J Affect Disord"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03626-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03626-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03626-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T13:02:28Z","timestamp":1735563748000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03626-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3626"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03626-5","relation":{},"ISSN":["1432-069X"],"issn-type":[{"type":"electronic","value":"1432-069X"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"1 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"161"}}